市場調査レポート

癌ワクチンおよび循環腫瘍細胞(CTC)市場:2011年

Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

発行 SELECTBIO, Ltd. 商品コード 144375
出版日 ページ情報 英文 139 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
癌ワクチンおよび循環腫瘍細胞(CTC)市場:2011年 Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report
出版日: 2011年01月20日 ページ情報: 英文 139 Pages
概要

当レポートでは、循環腫瘍細胞(CTC)市場の技術および市場環境を分析し、CTCの特徴、検出、分析手法などを紹介しながら、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 癌ワクチン:技術および市場分析

  • 癌免疫療法概要
  • 癌免疫療法における歴史的マイルストーン
  • 癌ワクチンの分類
  • 腫瘍関連抗原
  • 腫瘍特異性抗原
  • 抗癌ワクチン戦略
  • 失敗した治療用癌ワクチン候補
  • 癌ワクチンの成功率を上げるための戦略
  • 癌ワクチン市場概要
  • 米国FDA認可の癌ワクチン:予防および治療
  • 様々な国で認可された治療用癌ワクチン
  • 第3相治験における癌ワクチンパイプライン
  • 早期(第1相、第2相)パイプライン
  • 前臨床試験パイプライン
  • 個別化ワクチン

第3章 循環腫瘍細胞(CTC):技術および市場分析

  • 転移および上皮から間葉への変化
  • CTCとは
  • CTCとDTC
  • CTCの臨床的適切性
  • CTCの特徴
  • CTCの検出と診断
  • CTCの生物学
  • CTC分析手法
  • CTC濃縮、検出、特性化手法
  • CTC検出のためのマイクロ流体装置
  • CTC分析に関わる治験

付録:調査方法

目次

This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.

Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination - either preventative or therapeutic.

This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.

Extensive Worldwide Technical and Market Analyses Presented in this Report:

  • Classification and Characterization of Cancer Vaccines
  • Various Approaches for the Generation of Cancer Vaccines
  • Anti-Cancer Vaccination Strategies
  • Tumor Associated Antigens (TAAs)
  • Tumor Specific Antigens (TSAs)
  • Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure
  • Strategies to Improve Success of Cancer Vaccines
  • US FDA-Approved Cancer Vaccines
  • Therapeutic Cancer Vaccines Approved in Various Countries Around the World
  • Cancer Vaccine Pipeline in Late-Stage Clinical Trials
  • Cancer Vaccine Pipeline in Early-Stage Clinical Trials
  • Pre-Clinical Cancer Vaccine Pipeline
  • Personalized Cancer Vaccination Strategies
  • Biology and Characteristics of CTCs
  • Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs
  • More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report

Table of Contents

Chapter I. Executive Overview

Chapter II. Cancer Vaccines: Technology & Market Analysis

  • Cancer Immunotherapy Overview
  • Historical Milestones in Cancer Immunotherapy
  • Classification of Cancer Vaccines
  • Tumor Associated Antigens (TAAs)
  • Tumor Specific Antigens (TSAs)
  • Anti-Cancer Vaccination Strategies
  • Failed Therapeutic Cancer Vaccine Candidates
  • Strategies to Improve Success of Cancer Vaccines
  • Cancer Vaccines Market Overview
  • US FDA-Approved Cancer Vaccines: Preventative & Therapeutic
  • Therapeutic Cancer Vaccines Approved in Various Countries
  • Cancer Vaccine Pipeline in Phase III Clinical Trials
  • Early Stage (Phases I & II) Pipeline
  • Pre-Clinical Pipeline
  • Personalized Vaccines

Chapter III. Circulating Tumor Cells (CTCs): Technology & Market Analysis

  • Metastasis and Epithelial-to-Mesenchymal Transition (EMT)
  • What are CTCs?
  • CTCs vs. DTCs
  • Clinical Relevance of CTCs
  • Characteristics of CTCs
  • Detection and Diagnostics of CTCs
  • Biology of CTCs
  • CTC Analysis Methodologies
  • CTC Enrichment, Detection, and Characterization Methods
  • Microfluidic Devices for CTC Detection
  • Clinical Trials Involving CTC Analysis

Appendix I. Research Methodology

Back to Top